Russell Investments Group
OTLK icon

Russell Investments Group’s Outlook Therapeutics OTLK Stock Holding History

Russell Investments Group’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,498
Closed -$16.4K – 4233
2025
Q3 		$16.4K Sell
15,498
-8,979
-37% -$15.5K ﹤0.01% 3653
2025
Q2 		$39.2K Buy
24,477
+21,941
+865% +$35K ﹤0.01% 3037
2025
Q1 		$3.09K Sell
2,536
-14,632
-85% -$25.7K ﹤0.01% 3447
2024
Q4 		$32.4K Buy
17,168
+17,119
+34,937% +$70.4K ﹤0.01% 2918
2024
Q3 		$262 Buy
+49
New +$359 ﹤0.01% 3617

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group's OTLK Position: Q4 2025 in Review

Russell Investments Group sold out of Outlook Therapeutics (OTLK) in Q4 2025, closing a stake of 15,498 shares — an estimated $16.4K sold.

Russell Investments Group first reported a position in OTLK in Q3 2024 and held it in 5 quarters. The position peaked at $39.2K in Q2 2025. 53 funds tracked by Wall St. Rank hold OTLK as of Q4 2025.

  • Russell Investments Group reported no remaining Outlook Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Russell Investments Group sold 15,498 Outlook Therapeutics shares in Q4 2025, an estimated $16.4K.
  • Russell Investments Group first reported a position in Outlook Therapeutics in Q3 2024 and held it in 5 quarters.
  • Russell Investments Group's Outlook Therapeutics position peaked at $39.2K in Q2 2025.
  • 53 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2025.

Based on Russell Investments Group's 13F filing for Q4 2025, filed 17 Feb 2026.